Loading
A phase 2 trial of Apalutamide in salivary gland cancers, run by Janssen Pharmaceutical K.K., active and no longer recruiting.
A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma is a phase 2 interventional study registered as NCT04325828 by Janssen Pharmaceutical K.K., with 31 participants enrolled, started 2020-04-07 and due to reach its primary completion in 2021-06-09. Interventions recorded: Apalutamide and GnRH Agonist. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
31 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2022-07-06), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Response Rate (ORR)primary | Apalutamide + Goserelin | 24 | 25% | - | - | link |
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Johnson & Johnson and the tag pipeline.
Shares Salivary gland cancers and the tag pipeline.
Shares Apalutamide and the tag pipeline.